Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

427
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
427
Clinical Trials01:16

Clinical Trials

10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

975
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
975
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

269
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
269
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

263
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

International study of Coronary Microvascular Angina (iCorMicA): a registry-based diagnostic study and nested randomized trial.

American heart journal·2026
Same author

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same author

Probability of a timely vocal response in mother-infant interaction and later psychiatric diagnosis: A case-control study.

PloS one·2026
Same author

Endotype-informed therapy and effects on illness perception and psychological health in patients with chest pain and no obstructive coronary artery disease.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study.

The Lancet. Respiratory medicine·2026
Same author

External validation of the BAN-ADHF diuretic-resistance score in the DAPA-RESIST clinical trial.

British journal of clinical pharmacology·2026

相关实验视频

Updated: Jan 31, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K

在初级皮肤冠状动脉干预期间低剂量冠状动脉高位素对急性心肌梗塞患者微血管阻塞的影响:随机临床试验

Peter J McCartney1,2, Hany Eteiba1,2, Annette M Maznyczka1,2

  • 1British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

JAMA
|January 9, 2019
PubMed
概括
此摘要是机器生成的。

在患有ST段升高心肌梗塞 (STEMI) 的患者中,低剂量的冠心内高血压剂并没有降低微血管阻塞. 这项研究不支持在STEMI的初级穿皮干预中使用alteplase作为辅助治疗.

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

相关实验视频

Last Updated: Jan 31, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

科学领域:

  • 心脏病学
  • 干预心脏病学
  • 心血管成像

背景情况:

  • 微血管阻塞 (MVO) 是急性ST段升高心肌梗塞 (STEMI) 的常见并发症.
  • 在心肌梗塞后,MVO与不良临床结果有关.
  • 早期的再输血疗法旨在恢复血液流动,但可能受到MVO的限制.

研究的目的:

  • 评估低剂量冠状动脉中高血压剂在STEMI患者中降低MVO的疗效.
  • 确定在初级穿皮冠状动脉干预 (PCI) 期间早期给予阿尔特是否改善了微血管功能.

主要方法:

  • 一个随机的,剂量范围的试验,涉及440名STEMI患者在症状出现后6小时内.
  • 在初级PCI期间,患者接受了安慰剂,10 mg的阿尔特普拉斯或20 mg的阿尔特普拉斯输入.
  • 使用心磁共振成像 (MRI) 在手术后2 - 7天评估了微血管阻塞.

主要成果:

  • 主要结局,小血管阻塞,在20毫克的阿尔特普拉斯组 (3.5%) 和安慰剂组 (2.3%) 之间没有显著差异 (P=.32).
  • 在10毫克阿尔特 (2,6%) 和安慰剂 (2,3%) 之间没有显著差异 (P=.74).
  • 在所有组中,主要心脏不良事件的发生率都相似.

结论:

  • 在初级PCI期间给予辅助的低剂量冠状动脉高血压酶并没有降低STEMI患者的微血管阻塞.
  • 这些发现不支持使用这种治疗策略来改善STEMI的微血管结果.
  • 可能需要进一步的研究来探索减轻STEMI中MVO的替代策略.